Eli Lilly and Biogen announced on March 31, 2026, that they will spend nearly $12 billion combined to acquire specialized biotechnology companies. Eli Lilly intends to pay $6.3 billion to acquire Centessa Pharmaceuticals, while Biogen has agreed to a $5.6 billion deal for Apellis Pharmaceuticals. Both transactions emphasize a growing corporate hunger for immunology and neurological sleep disorder treatments within the global pharmaceutical sector.
Indianapolis-based Eli Lilly confirmed its intent to purchase Centessa for $38 per share in an all-cash transaction. Centessa maintains dual headquarters in London and Boston and has prioritized the development of treatments for sleeping conditions. Centessa shares rose sharply on the news, reflecting a 38% premium over the previous day closing price.
Biogen reached its own agreement to purchase Apellis for $41 per share. Investors noted the meaningful valuation hike, as the offer more than doubles the closing price Apellis maintained on Monday. Apellis focuses primarily on immunology drugs, specifically targeting vision loss associated with aging.
Specialized drug pipelines are commanding higher prices than ever.
Eli Lilly Expands Sleep Disorder Pipeline with Centessa
Lilly's acquisition of Centessa targets the competitive market for narcolepsy and other sleep-related disorders. Centessa launched publicly in 2021 with an ambitious portfolio of more than a dozen distinct programs. Over several years, the company narrowed its focus to disorders that impair a patient's ability to remain awake during normal hours. Experimental drugs currently in the Centessa pipeline aim to regulate sleep patterns through novel chemical pathways.
Financial terms of the deal suggest Lilly is willing to pay heavily for regulatory success. Centessa's agreement includes a base price of $6.3 billion, but total compensation could rise to $47 per share if specific drugs win approval from the U.S. Food and Drug Administration. Milestone payments could add $1.5 billion to the final cost of the acquisition. Centessa stockholders stand to benefit from these contingent value rights if clinical trials yield positive data in the coming months.
Executives at Eli Lilly have signaled that the Centessa portfolio complements their existing efforts in metabolic and neurological health. Centessa's transition from a broad-spectrum biotech firm to a specialized sleep medicine developer made it an attractive target for consolidation. Sleeping disorders represent a huge unmet medical need in Western markets where productivity and cognitive health are increasingly prioritized.
Lilly's cash reserves allowed for a swift negotiation process that valuation experts say reflects the urgency of big pharma to secure patent-protected assets. Centessa's recent average share price over the last 30 days was approximately 40.5% lower than the offer price. Cash remains the preferred medium for these high-stakes transactions in 2026.
Biogen Targets Vision Loss in Apellis Acquisition
Biogen's purchase of Apellis Pharmaceuticals centers on Syfovre, an immunology drug designed to treat geographic atrophy. Geographic atrophy is an advanced form of age-related macular degeneration that causes the destruction of retinal cells. Immune system dysfunction typically drives this condition, leading to permanent vision loss for millions of elderly patients. Syfovre received initial approval in 2023 and has already demonstrated commercial viability.
Apellis recorded $587 million in sales for Syfovre during the previous fiscal year. Biogen expects the drug to serve as a foundation for its expanding immunology division. Purchase terms include an upfront payment of $5.6 billion, but the total could climb if Syfovre hits specific sales thresholds. Apellis shareholders may receive an additional $4 per share based on the performance of the macular degeneration treatment.
Retinal health has become a battleground for large pharmaceutical firms seeking to replace revenue lost to patent expirations. Syfovre treats the underlying immune response that causes cell death in the eye. Biogen has struggled with its primary neurology portfolio in recent years and needs these commercial assets to stabilize its balance sheet. This acquisition provides Biogen with immediate cash flow from an already approved product.
Market Premia and Conditional Payment Structures
Valuations for both Apellis and Centessa indicate a high-level of competition for mid-cap biotechnology firms. Biogen paid more than double the market value for Apellis, a move that surprised some industry analysts. Eli Lilly opted for a more traditional 38% premium for Centessa. Differences in these premiums often reflect the stage of the drug development process. Apellis already has a drug on the market, whereas Centessa is still navigating the experimental phase.
Contingent value rights have become a standard feature in 2026 pharmaceutical deals. These structures protect the acquiring company from overpaying for failed clinical trials while offering shareholders a share of the upside if a drug succeeds. Biogen and Lilly both used these mechanisms to bridge the gap between their own internal valuations and the expectations of biotech boards. Shareholders in the UK and US generally favor these structures in high-risk sectors like drug development.
Institutional investors have reacted positively to the disciplined use of cash in these deals. Biogen's $41 per share offer reflects a calculated bet on the long-term growth of the geographic atrophy market. Lilly's $38 per share offer for Centessa acknowledges the risks inherent in sleep medicine research. Success depends entirely on the ability of these specialized firms to meet rigorous clinical endpoints.
Corporate Consolidation in Specialized Therapeutic Markets
Large pharmaceutical companies are increasingly acting as holding companies for smaller, more innovative research entities. Eli Lilly and Biogen are following a pattern of buying innovation because internal research and development often move too slowly. Centessa and Apellis are products of a venture capital ecosystem that rewards singular focus on specific biological pathways. Once these pathways are proven, big pharma uses its enormous distribution networks to scale the products.
Consolidation in the immunology space shows no signs of slowing down. Companies like Biogen need to diversify their revenue streams to protect against price negotiations and generic competition. Syfovre's nearly $600 million in annual sales provide a solid foundation for future growth. Narcolepsy treatments represent a different but equally lucrative opportunity for Eli Lilly as it expands beyond its traditional strongholds in diabetes and weight loss.
Global headquarters for these firms are now split between traditional hubs like Boston and emerging international centers in the UK. This geographical diversity allows companies to tap into different talent pools and regulatory environments. Smaller biotech firms now frequently design their business models with the ultimate goal of being acquired by a giant like Lilly or Biogen. Direct acquisition has replaced the initial public offering as the primary exit strategy for successful biotechnology startups.
The Elite Tribune Strategic Analysis
Big pharma's sudden $12 billion spending spree is not a sign of industrial strength, but rather a confession of internal creative bankruptcy. Why does a giant like Eli Lilly needs to spend $6.3 billion to find a narcolepsy drug that a five-year-old startup already figured out? The answer lies in the bloated, risk-averse nature of legacy corporate laboratories. These giants have transformed into glorified private equity firms that happen to wear lab coats. They wait for small, nimble teams to take the real scientific risks, then they swoop in with their cash reserves to buy the results once the danger has passed.
Biogen's move to pay a 100% premium for Apellis is particularly desperate. It suggests a management team that is terrified of its own pipeline's future. Paying double the market price for an immunology firm indicates that Biogen has no confidence in its internal ability to generate a blockbuster drug. While shareholders might cheer the immediate portfolio expansion, the long-term cost is the erosion of genuine scientific discovery within the largest players in the industry. The situation amounts to the end of the era of the great corporate lab.
The industry is now a two-tier system of innovators and acquirers. Innovation is the domain of the small, while acquisition is the only trick left for the large. If this trend continues, the cost of medicine will remain artificially high to subsidize the large premiums paid during these mergers. It is a cycle of inefficiency that rewards financial engineering over laboratory breakthroughs. Expect more of the same as the patent cliff approaches for the rest of the industry's aging blockbusters. Science is now a commodity to be bought, not a process to be led.